在痛风管理中加用尿液碱化治疗对黄嘌呤氧化酶抑制剂的影响:一项前瞻性队列研究
这项前瞻性队列研究纳入385例开始非布司他降尿酸治疗的痛风男性患者(尿pH<6.2),按患者意愿加用或不加用枸橼酸盐混合物碱化尿液。第12周时,碱化组尿白蛋白肌酐比显著低于对照组,痛风发作更少、疼痛视觉模拟评分更低,甘油三酯更低、高密度脂蛋白胆固醇更高,所需非布司他剂量约低20%,而血尿酸达标率无显著差异。
要点
- 碱化组第12周尿白蛋白肌酐比显著低于对照组(P<0.001),估算肾小球滤过率无显著差异。
- 碱化组痛风发作更少、疼痛视觉模拟评分更低(P<0.001),所需非布司他剂量约低20%。
- 碱化组甘油三酯更低(P<0.01)、高密度脂蛋白胆固醇更高(P<0.001),其他代谢结局无差异。
核心结论
- 在非布司他治疗的尿pH偏低的痛风男性患者中,碱化尿液与更低的尿白蛋白肌酐比、更少的痛风发作及改善的血脂谱相关。
研究设计与样本
- 前瞻性队列研究纳入385例开始非布司他降尿酸治疗的痛风男性患者(尿pH<6.2),非布司他起始20 mg/日,血尿酸≥360 µmol/l时加至40 mg/日。
- 按患者意愿决定是否加用碱化治疗,碱化方案为枸橼酸盐混合物3.5 g每日两次,每4周随访至第12周,主要结局为第12周尿白蛋白肌酐比。
- 共343例完成第12周随访,其中碱化组137例、对照组206例。
主要发现
- 第12周时碱化组所需非布司他剂量较对照组约低20%,而血尿酸达标<360 µmol/l无显著差异。
- 碱化组尿pH自第4周起显著升高(P<0.001)。
- 第12周碱化组尿白蛋白肌酐比显著低于对照组(P<0.001),估算肾小球滤过率无显著差异。
- 碱化组痛风发作更少、疼痛视觉模拟评分更低(P<0.001)。
- 碱化组血清甘油三酯更低(P<0.01)、高密度脂蛋白胆固醇更高(P<0.001),其他代谢结局无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gout patients frequently have decreased urine pH, related to metabolic syndrome (MetS) and chronic kidney disease. Here, we aimed to investigate whether the addition of urine alkalization to urate-lowering therapy (ULT) is associated with improvements in albuminuria, gout flares or MetS outcomes in men with gout and low urinary pH (pH < 6.2). METHODS: A prospective cohort study enrolled 385 participants starting ULT with febuxostat (initially 20 mg daily, escalated to 40 mg daily if serum urate ≥360 µmol/l), with or without alkalization based on patient preference using a 3.5 g bid citrate mixture. Participants were followed every 4 weeks to week 12. The primary outcome was urine albumin-to-creatinine ratio (UACR) at week 12. RESULTS: In total, 343 participants completed the week 12 visit (137 alkalization, 206 controls). At week 12, compared with controls, participants receiving alkalization required a significantly lower febuxostat dose (by ∼20%) but had no significant difference in serum urate at target <360 µmol/l. Urine pH increased significantly in the alkalization group from week 4 (P < 0.001). At week 12, the alkalization group had a significantly lower UACR compared with control (P < 0.001), without significantly different eGFR. Participants in the alkalization group experienced fewer gout flares and had lower pain visual analogue scale scores (P < 0.001). There were lower serum triglyceride levels (P < 0.01) and higher HDL-C levels (P < 0.001) in the alkalization group. No other differences in metabolic outcomes were observed. CONCLUSION: Urine alkalization was associated with lower UACR, fewer gout flares, and improved serum lipid profile in febuxostat-treated men with gout and low urine pH. TRIAL REGISTRATION: ChiCTR, http://www.chictr.org.cn, ChiCTR2100043573.
引用
- Wang C, Guo K, Dalbeth N, et al. Impact of adding urine alkalization therapy to xanthine oxidase inhibitor in gout management: a prospective cohort study. Rheumatology (Oxford). 2025. PMID: 39932882. doi:10.1093/rheumatology/keaf091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。